MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
0.6610
-0.0496
-6.98%
After Hours: 0.6799 +0.0189 +2.86% 19:59 08/27 EDT
OPEN
0.6782
PREV CLOSE
0.7106
HIGH
0.6980
LOW
0.5200
VOLUME
838.50K
TURNOVER
--
52 WEEK HIGH
28.50
52 WEEK LOW
0.5200
MARKET CAP
3.04M
P/E (TTM)
-0.0288
1D
5D
1M
3M
1Y
5Y
1D
*Artelo Biosciences: Reverse Split Being Effected in Order to Increase Price Per Shr of Common Stk to Improve Marketability and Liquidity >ARTL
Dow Jones · 17h ago
Weekly Report: what happened at ARTL last week (0817-0821)?
Weekly Report · 3d ago
Artelo secures Japan patent allowance for ART27.13 commercial formulation
TipRanks · 08/20 13:35
Artelo Biosciences Issued Notification Of Allowance From Japanese Patent Office With Decision To Grant Patent Application For Commercial Formulation Of ART27.13
Benzinga · 08/20 12:53
Artelo Biosciences Receives U.S. Patent Notice Of Allowance For ART27.13; Stock Up
NASDAQ · 08/18 07:14
Artelo Biosciences receives notice of allowance from USPTO
TipRanks · 08/17 13:15
Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
Benzinga · 08/17 12:56
Weekly Report: what happened at ARTL last week (0810-0814)?
Weekly Report · 08/17 09:42
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.